SG Americas Securities LLC Buys 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

SG Americas Securities LLC increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 204.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,917 shares of the biopharmaceutical company’s stock after acquiring an additional 8,673 shares during the period. SG Americas Securities LLC’s holdings in Intra-Cellular Therapies were worth $1,079,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at $32,000. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the period. Capital Performance Advisors LLP purchased a new position in shares of Intra-Cellular Therapies in the third quarter worth about $74,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies in the third quarter valued at approximately $97,000. Finally, Quarry LP lifted its stake in shares of Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 1,300 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.2 %

ITCI opened at $127.00 on Wednesday. The business’s fifty day simple moving average is $94.97 and its 200 day simple moving average is $83.51. Intra-Cellular Therapies, Inc. has a 52 week low of $62.78 and a 52 week high of $128.00. The stock has a market cap of $13.46 billion, a PE ratio of -145.98 and a beta of 0.70.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Intra-Cellular Therapies’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.25) earnings per share. As a group, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.

Analyst Ratings Changes

ITCI has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Thursday, January 23rd. They issued a “hold” rating for the company. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Morgan Stanley upped their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.15.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.